MKMustafa Kahraman

Mustafa Kahraman

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Mustafa Kahraman has a total of 89 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    TransfoRNA: Navigating the Uncertainties of Small RNA Annotation with an Adaptive Machine Learning Strategy

    by Yasser Taha, Julia Jehn, Mustafa Kahraman, Maurice Frank, Marco Heuvelman, Rastislav Horos, Christopher Yau, Bruno Steinkraus, Tobias Sikosek

    Small RNAs hold crucial biological information and have immense diagnostic and therapeutic value. While many established annotation tools focus on microRNAs, there are myriads of other small RNAs that are currently underutilized. These small RNAs can be difficult to annotate, as ground truth is limited and well-established mapping and mismatch rules are lacking. TransfoRNA is a machine learning framework based on Transformers that explores an alternative strategy. It uses common annotation tools to generate a small seed of high-confidence training labels, while then expanding upon those labels iteratively. TransfoRNA learns sequence-specific representations of all RNAs to construct a similarity network which can be interrogated as new RNAs are annotated, allowing to rank RNAs based on their familiarity. While models can be flexibly trained on any RNA dataset, we here present a version trained on TCGA (The Cancer Genome Atlas) small RNA sequences and demonstrate its ability to add annotation confidence to an unrelated dataset, where 21% of previously unannotated RNAs could be annotated. Relative to its training data, TransfoRNA could boost high-confidence annotations in TCGA by ∼50% while providing transparent explanations even for low-confidence ones. It could learn to annotate 97% of isomiRs from just single examples and confidently identify new members of other familiar classes with high accuracy, while reliably rejecting false RNAs. All source code is available at https://github.com/gitHBDX/TransfoRNA and can be executed at Code Ocean ( https://codeocean.com/capsule/5415298/ ). An interactive website is available at www.transforna.com . GRAPHICAL


  • Open Access

    Validation of human microRNA target pathways enables evaluation of target prediction tools

    by Fabian Kern, Lena Krammes, Karin Danz, Caroline Diener, Tim Kehl, Oliver Küchler, Tobias Fehlmann, Mustafa Kahraman, Stefanie Rheinheimer, Ernesto Aparicio-Puerta, et al.

    MicroRNAs are regulators of gene expression. A wide-spread, yet not validated, assumption is that the targetome of miRNAs is non-randomly distributed across the transcriptome and that targets share functional pathways. We developed a computational and experimental strategy termed high-throughput miRNA interaction reporter assay (HiTmIR) to facilitate the validation of target pathways. First, targets and target pathways are predicted and prioritized by computational means to increase the specificity and positive predictive value. Second, the novel webtool miRTaH facilitates guided designs of reporter assay constructs at scale. Third, automated and standardized reporter assays are performed. We evaluated HiTmIR using miR-34a-5p, for which TNF- and TGFB-signaling, and Parkinson's Disease (PD)-related categories were identified and repeated the pipeline for miR-7-5p. HiTmIR validated 58.9% of the target genes for miR-34a-5p and 46.7% for miR-7-5p. We confirmed the targeting by measuring the endogenous protein levels of targets in a neuronal cell model. The standardized positive and negative targets are collected in the new miRATBase database, representing a resource for training, or benchmarking new target predictors. Applied to 88 target predictors with different confidence scores, TargetScan 7.2 and miRanda outperformed other tools. Our experiments demonstrate the efficiency of HiTmIR and provide evidence for an orchestrated miRNA-gene targeting.


  • Open Access

    Common diseases alter the physiological age-related blood microRNA profile

    by Tobias Fehlmann, Benoit Lehallier, Nicholas Schaum, Oliver Hahn, Mustafa Kahraman, Yongping Li, Nadja Grammes, Lars Geffers, Christina Backes, Rudi Balling, et al.

    Aging is a key risk factor for chronic diseases of the elderly. MicroRNAs regulate post-transcriptional gene silencing through base-pair binding on their target mRNAs. We identified nonlinear changes in age-related microRNAs by analyzing whole blood from 1334 healthy individuals. We observed a larger influence of the age as compared to the sex and provide evidence for a shift to the 5’ mature form of miRNAs in healthy aging. The addition of 3059 diseased patients uncovered pan-disease and disease-specific alterations in aging profiles. Disease biomarker sets for all diseases were different between young and old patients. Computational deconvolution of whole-blood miRNAs into blood cell types suggests that cell intrinsic gene expression changes may impart greater significance than cell abundance changes to the whole blood miRNA profile. Altogether, these data provide a foundation for understanding the relationship between healthy aging and disease, and for the development of age-specific disease biomarkers.


  • Open Access

    Deep sncRNA-seq of the PPMI cohort to study Parkinson’s disease progression

    by Fabian Kern, Tobias Fehlmann, Ivo Violich, Eric Alsop, Elizabeth Hutchins, Mustafa Kahraman, Nadja Liddy Grammes, Pedro Guimarães, Christina Backes, Kathleen Poston, et al.

    Coding and non-coding RNAs have diagnostic and prognostic importance in Parkinson’s diseases (PD). We studied circulating small non-coding RNAs (sncRNAs) in 7, 003 samples from two longitudinal PD cohorts (Parkinson’s Progression Marker Initiative (PPMI) and Luxembourg Parkinson’s Study (NCER-PD)) and modelled their influence on the transcriptome. First, we sequenced sncRNAs in 5, 450 blood samples of 1, 614 individuals in PPMI. The majority of 323 billion reads (59 million reads per sample) mapped to miRNAs. Other covered RNA classes include piRNAs, rRNAs, snoRNAs, tRNAs, scaRNAs, and snRNAs. De-regulated miRNAs were associated with the disease and disease progression and occur in two distinct waves in the third and seventh decade of live. Originating mostly from a characteristic set of immune cells they resemble a systemic inflammation response and mitochondrial dysfunction, two hallmarks of PD. By profiling 1, 553 samples from 1, 024 individuals in the NCER-PD cohort using an independent technology, we validate relevant findings from the sequencing study. Finally, network analysis of sncRNAs and transcriptome sequencing of the original cohort identified regulatory modules emerging in progressing PD patients.


  • Open Access

    Limited Long-Term Impact of Insect Venom Immunotherapy on the Micro-RNA Landscape in Whole Blood

    by P Karpinski, M Kahraman, N Ludwig, P Skiba, M Kosinska, M Rosiek-Biegus, E Królewicz, B Panaszek, M Nittner-Marszalska, N Blin, et al.

    To perform a genome-wide characterization of changes in microRNA (miRNA) expression during the course of venom immunotherapy (VIT). miRNA was isolated from the whole-blood of 13 allergic patients and 14 controls, who experienced no allergic reaction upon stings by honeybees and wasps. We analyzed 2549 miRNAs from the whole blood of these patients prior to VIT and 12 months after the start of VIT. The results for differential expression obtained on a microarray platform were confirmed by quantitative real-time PCR. Out of the 13 patients, 8 had a negative allergic reaction with VIT, thus indicating that this approach was successful. By comparing time points before and 12 months after ultrarush VIT, correlation analysis and principal component analysis both indicated a limited effect of VIT on the overall miRNA expression pattern. Volcano plot analysis based on raw P values revealed few deregulated miRNAs, most of which were increasingly expressed after VIT as compared with before VIT. Based on the 50 most altered miRNAs, no clear clustering was observed before or after VIT. Our results indicate an overall reduced effect of VIT on the miRNA expression pattern in whole blood.


  • Open Access

    MicroRNA in diagnosis and therapy monitoring of early-stage triple-negative breast cancer

    by Mustafa Kahraman, Anne Röske, Thomas Laufer, Tobias Fehlmann, Christina Backes, Fabian Kern, Jochen Kohlhaas, Hannah Schrörs, Anna Saiz, Cassandra Zabler, et al.

    Breast cancer is a heterogeneous disease with distinct molecular subtypes including the aggressive subtype triple-negative breast cancer (TNBC). We compared blood-borne miRNA signatures of early-stage basal-like (cytokeratin-CK5-positive) TNBC patients to age-matched controls. The miRNAs of TNBC patients were assessed prior to and following platinum-based neoadjuvant chemotherapy (NCT). After an exploratory genome-wide study on 21 cases and 21 controls using microarrays, the identified signatures were verified independently in two laboratories on the same and a new cohort by RT-qPCR. We differentiated the blood of TNBC patients before NCT from controls with 84% sensitivity. The most significant miRNA for this diagnostic classification was miR-126-5p (two tailed t-test p-value of 1.4 × 10−5). Validation confirmed the microarray results for all tested miRNAs. Comparing cancer patients prior to and post NCT highlighted 321 significant miRNAs (among them miR-34a, p-value of 1.2 × 10−23). Our results also suggest that changes in miRNA expression during NCT may have predictive potential to predict pathological complete response (pCR). In conclusion we report that miRNA expression measured from blood facilitates early and minimally-invasive diagnosis of basal-like TNBC. We also demonstrate that NCT has a significant influence on miRNA expression. Finally, we show that blood-borne miRNA profiles monitored over time have potential to predict pCR.


  • Open Access

    Genome-Wide MicroRNA Expression Profiles in COPD: Early Predictors for Cancer Development

    by Andreas Keller, Tobias Fehlmann, Nicole Ludwig, Mustafa Kahraman, Thomas Laufer, Christina Backes, Claus Vogelmeier, Caroline Diener, Frank Biertz, Christian Herr, et al.

    Chronic obstructive pulmonary disease (COPD) significantly increases the risk of developing cancer. Biomarker studies frequently follow a case-control set-up in which patients diagnosed with a disease are compared to controls. Longitudinal cohort studies such as the COPD-centered German COPD and SYstemic consequences-COmorbidities NETwork (COSYCONET) study provide the patient and biomaterial base for discovering predictive molecular markers. We asked whether microRNA (miRNA) profiles in blood collected from COPD patients prior to a tumor diagnosis could support an early diagnosis of tumor development independent of the tumor type. From 2741 participants of COSYCONET diagnosed with COPD, we selected 534 individuals including 33 patients who developed cancer during the follow-up period of 54 months and 501 patients who did not develop cancer, but had similar age, gender and smoking history. Genome-wide miRNA profiles were generated and evaluated using machine learning techniques. For patients developing cancer we identified nine miRNAs with significantly decreased abundance (two-tailed unpaired t-test adjusted for multiple testing P < 0.05), including members of the miR-320 family. The identified miRNAs regulate different cancer-related pathways including the MAPK pathway (P = 2.3 × 10−5). We also observed the impact of confounding factors on the generated miRNA profiles, underlining the value of our matched analysis. For selected miRNAs, qRT-PCR analysis was applied to validate the results. In conclusion, we identified several miRNAs in blood of COPD patients, which could serve as candidates for biomarkers to help identify COPD patients at risk of developing cancer.